Alexander Katz is the principal investigator of the Genomic Ascertainment Cohort (TGAC) a large-scale resource enabling predictive genomic research. Dr. Katz leads a team of clinicians and bioinformaticians in implementing clinical research at the NIH clinical center that aims to predict phenotype from genotype. TGAC’s approach includes aggregating genomic data from a phenotypically unselected population and formulating hypotheses based on genomic variants of interest rather than phenotypic traits of interest. Dr. Katz is board certified in clinical genetics, molecular genetics, and internal medicine, having completed a clinical fellowship at the National Human Genome Research Institute and residency at the University of Michigan. He also holds a bachelor’s degree from the University of Virginia and a master’s degree in human genetics from the University of Michigan.
Clinical & Research Tools Showcase:
National Human Genome Research Institute, NIH
National Human Genome Research Institute aims to advance genomic research at the National Institutes of Health.
Piloting Predictive Medicine with TGAC
The Genomic Ascertainment Cohort (TGAC) represents a paradigm-shifting approach to clinical genomics research. By starting with a genomic variant of interest in an individual and performing deep targeted phenotyping, we predict phenotype from genotype - which ultimately can transform genomic medicine.
The PMWC 2022 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.